No injections. No reconstitution learning curve. BPC-157 is one of the few peptides with plausible oral bioavailability, and GHK-Cu has genuine human evidence as a topical. This is the lowest-barrier entry into peptide research — and it is not a compromise stack.
MOTS-c activates AMPK and drives mitochondrial biogenesis. SS-31 protects cardiolipin in the inner mitochondrial membrane and restores electron transport efficiency in aged mitochondria. One makes more mitochondria; the other fixes the ones you have.
Cerebrolysin is a peptide mixture with human RCT data for stroke and Alzheimer's. Semax is a registered Russian medicine for the same indications. Together they provide complementary neurotrophin support from two distinct mechanisms — one endogenous, one synthetic analog.
Three peptides that target three separate drivers of biological ageing: telomere attrition, thymic involution, and systemic repair capacity. The Khavinson Institute has studied two of them together in humans for over two decades.
CJC-1295 acts on the GHRH receptor. Ipamorelin acts on the ghrelin receptor. Together they trigger a synergistic GH pulse that neither produces as effectively alone — and Ipamorelin's selectivity means you don't get the cortisol and prolactin side effects of older secretagogues.
Semax drives focus and BDNF. Selank removes the anxiety that focus-enhancement often brings. Together they hit the same goal from opposite directions — and the mechanisms don't overlap.
BPC-157 builds the blood supply. TB-500 moves the cells in to do the work. These are the two most-studied repair peptides, and their mechanisms are directly complementary rather than redundant.